SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 18, 2011
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
|
PENNSYLVANIA
(State or Other Jurisdiction of
Incorporation)
|
|
1-14131
(Commission
File Number)
|
|
23-2472830
(I.R.S. Employer
Identification No.) |
| |
|
|
|
852 Winter Street
Waltham, Massachusetts
(Address of principal executive offices)
|
|
02451
(Zip Code) |
Registrant’s telephone number, including area code: (781) 609-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
þ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On
May 18, 2011, Alkermes, Inc. announced financial results for the fiscal year 2011 and
provided financial expectations for the fiscal year 2012. A copy of the press release is attached
hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the
Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item 8.01. Other Events.
On
May 9, 2011, Alkermes, Inc. announced the execution of a definitive agreement pursuant to which
Alkermes will merge with Elan Drug Technologies. In connection with the announcement of its fiscal
year 2011 financial results and expectations for fiscal year 2012, the expected financial and
operational impact of this recently announced merger transaction with Elan Drug Technologies are
discussed. This information is set forth in the press release attached hereto as Exhibit 99.1.
Important Additional Information and Where to Find It
This communication does not constitute an offer to sell, or the solicitation of an offer to sell,
or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any
sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
In connection with the proposed merger, Alkermes plc will file with the SEC a registration
statement on Form S-4 that will include a preliminary prospectus regarding the proposed merger and
Alkermes, Inc. will file with the SEC a proxy statement in respect of the proposed merger. After
the registration statement has been declared effective by the SEC, a definitive proxy
statement/prospectus will be mailed to Alkermes’ stockholders in connection with the proposed
merger. INVESTORS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL
AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER FILED WITH THE SEC
WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ALKERMES, EDT AND
THE PROPOSED MERGER. You may obtain a copy of the registration statement and the proxy
statement/prospectus (when available) and other related documents filed by Alkermes and Elan with
the SEC regarding the proposed merger as well as other filings containing information about
Alkermes, Elan and the merger, free of charge, through the web site maintained by the SEC at
www.sec.gov, by directing a request to Alkermes’ Investor Relations department at Alkermes, Inc.,
852 Winter Street, Waltham, Massachusetts 02451, Attn: Investor Relations or to Alkermes’ Investor
Relations department at (781) 609-6000 or by email to financial@alkermes.com. Copies of the proxy
statement/prospectus and the filings with the SEC that will be incorporated by reference in the
proxy statement/prospectus can also be obtained, when available, without charge, from Alkermes’
website at www.Alkermes.com under the heading “Investor Relations” and then under the heading “SEC
Filings”.
Participants in Solicitation
This communication is not a solicitation of a proxy from any Alkermes shareholder. Alkermes and its
directors, executive officers and certain other members of management and employees may, however,
be deemed to be participants in the solicitation of proxies in respect of the proposed merger.
Information regarding the persons who may, under the rules of the SEC, be considered participants
in the solicitation of proxies in respect of the proposed merger will be set forth in the
registration statement and the proxy statement/prospectus when it is filed with the SEC. You can
find information about Alkermes’ directors and executive officers in its definitive proxy
statements filed with the SEC on July 29, 2010. You can obtain free copies of these documents as
described above.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| |
|
|
| Exhibit |
|
|
| No. |
|
Description |
99.1
|
|
Press release issued by Alkermes, Inc. dated May 18, 2011
announcing financial results for the fiscal year 2011 and
financial expectations for the fiscal year 2012. |